Angelini Labopharm Announces the U.S. Launch of OLEPTRO™ for the Treatment of Major Depressive Disorder in Adults

Tuesday, August 10, 2010 Mental Health News J E 4
OLEPTRO™ Now Available as a New Treatment Option for MDD

For Media Inquiries (Angelini Labopharm)

For Labopharm Investor Relations Inquiries

Michael Parks

Lawrence Chamberlain

Vox Medica, Inc.

Investor Relations

Tel: (267) 885-3066

Tel:  (416) 815-0700

For Media Inquiries (Angelini)

Fabio Pieroni

Angelini Corporate Communications Director

Tel: +39 06 78053366



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Adis Journals Make Impressive Impact Factor Gains
S to Help Millions Get a Good Night...